Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells

BACKGROUND: Approximately 18–20% of all human breast cancers have overexpressed human epidermal growth factor receptor 2 (HER2). Standard clinical practice is to treat only overexpressed HER2 (HER2+) cancers with targeted anti-HER2 therapies. However, recent analyses of clinical trial data have foun...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yao, Burns, David J., Rich, Benjamin E., MacNeil, Ian A., Dandapat, Abhijit, Soltani, Sajjad M., Myhre, Samantha, Sullivan, Brian F., Lange, Carol A., Furcht, Leo T., Laing, Lance G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356237/
https://www.ncbi.nlm.nih.gov/pubmed/28302091
http://dx.doi.org/10.1186/s12885-017-3181-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356237/
https://www.ncbi.nlm.nih.gov/pubmed/28302091
http://dx.doi.org/10.1186/s12885-017-3181-0

Ejemplares similares